Hans-Peter Maerki

This inventor holds 29 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Pharmaceutical Compounds. Top assignee: Hoffmann-La Roche Inc.. Active years: 2002-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans-Peter Maerki. Retrieved from https://idiyas.com/inventor/hans-peter-maerki-twej6td8

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 2)

% Patents Active = 3.4

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 6.9

ph-index = 3

Forward Citations = 46(Granted Patents)

Location History:

Basle, CH (2005 - 2008)
Basel, CH (2002 - 2010)

Company Filing History:

29 out of 5,026

Hoffmann-La Roche Inc.

patents

Years Active: 2002-2010

Loading Chart...

Areas of Expertise:

Pharmaceutical Agents

Oxazole Derivatives

Indole Derivatives

Thiazole Derivatives

Pyrimidine Derivatives

Heteroaromate Inhibitors

Amide Derivatives

Aniline Derivatives

Phenyl Derivatives

Cyclohexane Derivatives

mGluR Antagonists

Triazine Derivatives

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7855194 - Pyrimidine, quinazoline, pteridine and triazine derivatives (2010-12-21),

2. 7772253 - Amide derivatives as somatostatin receptor 5 antagonists (2010-08-10),

3. 7645753 - Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives (2010-01-12),

4. 7495001 - Benzannelated derivatives, their manufacture and use as pharmaceutical agents (2009-02-24),

5. 7449483 - Heteroaromate OSC inhibitors (2008-11-11),

6. 7442791 - Aminoalkylamide substituted cyclohexyl derivatives (2008-10-28),

7. 7405236 - Indole derivatives comprising an acetylene group (2008-07-29),

8. 7348349 - Oxazole derivatives (2008-03-25),

9. 7345067 - Aniline derivatives, their manufacture and use as pharmaceutical agents (2008-03-18),

10. 7335687 - 2,3-Oxidosqualene-lanosterol cyclase inhibitors (2008-02-26),

11. 7265149 - Indolyl derivatives (2007-09-04),

12. 7253192 - Phenyl derivatives comprising an acetylene group (2007-08-07),

13. 7235572 - Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents (2007-06-26),

14. 7173043 - Heteroaromate OSC inhibitors (2007-02-06),

15. 7115611 - Phenyl derivatives, their manufacture and use as pharmaceutical agents (2006-10-03),

Title: Innovations and Contributions of Hans-Peter Maerki

Introduction

Hans-Peter Maerki, an esteemed inventor based in Basel, Switzerland, has made significant contributions to the field of pharmaceuticals through his innovative research and development. With a remarkable portfolio of 29 patents, Maerki's work focuses on creating new compounds for the treatment of diseases by modulating specific receptor subtypes.

Latest Patents

Among his latest patents are innovations related to pyrimidine, quinazoline, pteridine, and triazine derivatives. These inventions pertain to compounds that include pharmaceutically acceptable salts. The inventions are particularly relevant for their use in the treatment and prevention of diseases associated with the modulation of somatostatin receptor subtype 5 (SST5). Additionally, his patent on amide derivatives as somatostatin receptor 5 antagonists has also garnered attention, encompassing similar compounds and their pharmaceutical applications.

Career Highlights

Hans-Peter Maerki has built his career at Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His dedication to innovation has led to breakthroughs that impact patient care and treatment options, positioning him as a key figure in pharmaceutical research and development.

Collaborations

Throughout his career, Maerki has collaborated with accomplished professionals, including Alfred Binggeli and Jean Ackermann. These partnerships have fostered a creative and productive environment, enabling the advancement of pharmaceutical sciences and the successful development of new therapies.

Conclusion

In conclusion, Hans-Peter Maerki's contributions to the field of pharmaceuticals are noteworthy, reflecting his commitment to innovation and patient health. His extensive patent portfolio underscores his expertise and the impact of his work on modern medicine. Maerki continues to be a valuable asset to Hoffmann-La Roche Inc. and the pharmaceutical community at large.

Profile summary based on public USPTO records.